View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 3, 2020updated 12 Jul 2022 11:57am

Karyopharm announces positive results from multiple myeloma trial

Karyopharm Therapeutics has announced positive top-line results from the randomised Phase III BOSTON trial on patients suffering from multiple myeloma.

Karyopharm Therapeutics has announced positive top-line results from the randomised Phase III BOSTON trial on patients suffering from multiple myeloma.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial is assessing once-weekly XPOVIO (selinexor) along with once-weekly Velcade (bortezomib) and low-dose dexamethasone (SVd) against standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients who have received one to three prior lines of therapy.

The trial met its primary endpoint of a statistically significant increase in progression-free survival (PFS).

The median PFS in the SVd arm was found to be 13.93 months, compared to 9.46 months in the Vd arm, accounting for a 4.47 month (47%) increase in median PFS (hazard ratio=0.70; p=0.0066).

Researchers found that there were no new safety signals in the SVd arm and no imbalance in deaths between the two arms in the study.

Full top-line data will be presented at upcoming medical meetings.

Karyopharm president and chief scientific officer Sharon Shacham said: “We are thrilled to report these highly significant top-line results from the BOSTON study, the first randomised Phase III trial to demonstrate clinically and statistically significant activity of once-weekly XPOVIO in combination with a current standard of care treatment in patients with myeloma after one to three prior therapies.”

“In the study, patients on the SVd regimen lived 47% longer without their disease worsening, which we believe represents an important improvement in the treatment of patients with relapsed or refractory multiple myeloma.”

The company plans to submit the data to the US Food and Drug Administration (FDA) as part of a supplemental new drug application, which seeks to expand the approved indication for XPOVIO into second line treatment for patients suffering with relapsed or refractory multiple myeloma.

If the FDA gives approval, the SVd regimen is then claimed to become the only FDA-approved combination drug regimen that includes once-weekly Velcade therapy for relapsed myeloma.

In July 2019, XPOVIO secured accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four therapies prior and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

This indication has received accelerated approval based on the response rate.

Continued approval for this indication may depend upon the verification and description of clinical benefit in a confirmatory trial.

Karyopharm intends to submit data from the Phase III trial to act as this confirmatory study.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena